Swiss pharma hopes to bounce back from Q1 sales disappointment
Biotech will focus on diseases such as TB
Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
SMi Pharma Micro West Coast USA
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.